Press Releases

Filter Press Releases:



  • Rimidi and Lilly Collaborate to Personalize Solutions for People Using Insulin

    INDIANAPOLIS and ATLANTA, Dec. 14, 2017 /PRNewswire/ -- Rimidi, a digital health company that provides software and clinical analytics for chronic disease management, and Eli Lilly and Company (NYSE: LLY), a leader in diabetes care for more than 90 years, are coming together to develop provider-focused tools that will integrate personalized solutions for people who use insulin to manage their dia…

  • Lilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020

    INDIANAPOLIS, Dec. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its 2018 financial guidance, including low-single-digit revenue growth driven by volume from recently launched pharmaceutical products. The company also highlighted key events for the upcoming year, including continued progress on its pipeline. "Lilly is in the early stages of a growth period driven…

  • Lilly Announces 8 Percent Dividend Increase

    INDIANAPOLIS, Dec. 11, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today announced an 8 percent increase in its quarterly dividend. The dividend for the first quarter of 2018 will be $0.5625 per share on outstanding common stock. This raises the annual indicated rate to $2.25 per share.  The dividend is payable March 9, 2018, to shareholders of record at o…

  • FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults

    INDIANAPOLIS, Dec. 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) to review galcanezumab for the prevention of migraine in adults. Galcanezumab has been submitted for use as a once-monthly, self-administered injection via auto-injector pen or prefilled syringe. Lilly…

  • Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology

    INDIANAPOLIS, Dec. 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Kimberly Blackwell, M.D., one of the nation's leading breast cancer researchers, will join Lilly Oncology as vice president of early phase development and immuno-oncology on March 12, 2018.  Dr. Blackwell is currently professor of medicine and assistant professo…

  • Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer

    INDIANAPOLIS, Dec. 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced top-line results from its Phase 3 RAINFALL study of CYRAMZA® (ramucirumab) in combination with cisplatin and capecitabine or 5-FU (5-fluorouracil) in the first-line treatment of patients with HER2-negative metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The trial met its primary…

  • Lilly Initiates Clinical Trial to Evaluate the Functionality and Safety of its Automated Insulin Delivery System

    INDIANAPOLIS, Dec. 5, 2017 /PRNewswire/ -- Yesterday marked dosing of the first patient with type 1 diabetes in a feasibility study to evaluate the functionality and safety of an automated insulin delivery (AID) system in development by Eli Lilly and Company (NYSE: LLY). The AID system is part of the Connected Diabetes Ecosystem, which is being designed to make diabetes management easier by enabl…

  • Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis

    INDIANAPOLIS, Dec. 1, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment of adults with active psoriatic arthritis (PsA).1 Taltz was first approved by the FDA in March 2016 for the treatment of adult patients with moderate-to-severe plaque psoriasis who a…

  • Lilly Confirms Date and Conference Call for 2018 Financial Guidance Announcement

    INDIANAPOLIS, Nov. 20, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2018 on Wednesday, December 13, 2017. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial guidance. The conference call will begin at 10 a.m. Eastern time. Investors, media and the general publ…

  • Lilly to Participate in Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference

    INDIANAPOLIS, Nov. 17, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on Thursday, November 30, 2017. Dan Skovronsky, M.D., Ph.D., senior vice president of Clinical and Product Development at Lilly, will participate in a fireside chat at 4:15 p.m., Eastern time. A live audio webcast will be available on t…

  • Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

    RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 13, 2017 /PRNewswire/ -- New data presented today showed that Jardiance® reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease. These results, from a post-hoc analysis of the landmark EMPA-REG OUTCOME® trial, were shared as an oral presentation on…

  • Lilly Appoints Philip Johnson to Senior Vice President and Treasurer

    INDIANAPOLIS, Nov. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Philip Johnson has been appointed to senior vice president, Finance, and treasurer effective January 1, 2018. Johnson currently serves as vice president for Investor Relations at Lilly. He will report to Joshua Smiley, who will become senior vice president and chief financial officer effective January 1,…

  • New Data on FORTEO® (teriparatide [rDNA origin] injection) Showed Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis

    INDIANAPOLIS, Nov. 9, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data showing that treatment with FORTEO® for 24 months was associated with significantly fewer vertebral and clinical fractures (a composite of painful vertebral and non-vertebral fractures) compared with risedronate, a widely used oral bisphosphonate, in postmenopausal women with severe osteopor…

  • ACR/ARHP 2017: Long-Term Use of Lilly's Taltz® (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors

    INDIANAPOLIS, Nov. 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today patients with active psoriatic arthritis (PsA) treated with Taltz® (ixekizumab), who were previously intolerant or had inadequate responses to TNF inhibitors, showed improvements in the signs and symptoms of PsA across treatment groups for up to 52 weeks. Interim results from the extension period of…

  • ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo

    INDIANAPOLIS, Nov. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that patients with moderate-to-severe rheumatoid arthritis (RA) treated with baricitinib reported greater improvements in pain control when compared to Humira®* (adalimumab) or placebo. A new post-hoc analysis of the Phase 3 RA-BEAM study disclosing outcomes of p…

  • Lilly to Present New Data on Immunology Portfolio at ACR/ARHP Annual Meeting

    INDIANAPOLIS, Oct. 30, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that it will present new data for baricitinib and Taltz® (ixekizumab) at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting taking place Nov. 3-8, 2017, in San Diego, Calif. Lilly will feature new data for baricitinib in 17 abstracts, inclu…

  • Lilly To Participate In Credit Suisse 26th Annual Healthcare Conference

    INDIANAPOLIS, Oct. 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Credit Suisse 26th Annual Healthcare Conference on Tuesday, November 7, 2017. Jan Lundberg, Ph.D., executive vice president for science and technology and president of Lilly Research Laboratories, will participate in a fireside chat at 12:55 p.m., Eastern Time. A live audio webcast will be av…

  • Lilly Reports Third-Quarter Results, Announces Strategic Review of Elanco Animal Health

    INDIANAPOLIS, Oct. 24, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2017. $ in millions, except per share data Third Quarter % 2017 2016 Change Revenue $ 5,658.0 $ 5,191.7 9% Net Income - Reported 555.6 778.0…

  • Lilly announces $72 million investment in diabetes manufacturing in Indianapolis

    INDIANAPOLIS, Oct. 23, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to invest $72 million in an insulin manufacturing project at one of its Indianapolis facilities. The investment will be used to replace an existing insulin vial filling line and allow Lilly to meet growing demand for its insulins - including Humalog® (insulin lispro) and Humulin® (human i…

  • Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

    INDIANAPOLIS and TÜBINGEN, Germany, Oct. 18, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac's proprietary RNActive® technology. The companies will use messenger RNA (mRNA) technology that targets tu…

  • Lilly Declares Fourth-Quarter 2017 Dividend

    INDIANAPOLIS, Oct. 16, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2017 of $0.52 per share on outstanding common stock. The dividend is payable December 8, 2017, to shareholders of record at the close of business on November 15, 2017. About Eli Lilly and CompanyLilly is a global healthcare leader that un…

  • U.S. Patent and Trademark Office Rules In Lilly's Favor On Alimta Vitamin Regimen Patent

    INDIANAPOLIS, Oct. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTO) has ruled in the company's favor regarding patentability of the vitamin regimen for Alimta® (pemetrexed for injection). In the inter partes review (IPR) proceedings initiated by Neptune Generics, LLC and Sandoz In…

  • Additional Delivery of Insulin Ready for Distribution in Puerto Rico

    INDIANAPOLIS, Oct. 5, 2017 /PRNewswire/ -- Today, a new shipment of commercial medicines, including more than 36,000 vials and pens of insulin, arrived in Puerto Rico. The delivery by Eli Lilly and Company (NYSE: LLY) includes 3,000 vials for humanitarian distribution and enough commercial insulin to help re-stock operational pharmacies. Lilly's humanitarian donation now includes 5,400 insulin pe…

  • Lilly Confirms Date and Conference Call for Third-Quarter 2017 Financial Results Announcement

    INDIANAPOLIS, Oct. 2, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2017 on Tuesday, October 24, 2017. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 9 a.m. Eastern time. Investors, media an…

  • Lilly Announces Senior Leadership Appointments for Finance, Research & Development and Manufacturing

    INDIANAPOLIS, Sept. 29, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a number of leadership changes, promoting several experienced Lilly leaders to executive roles, effective in 2018. Josh Smiley has been promoted to senior vice president and chief financial officer and will become a member of Lilly's executive committee, effective January 1, 2018. Lilly announced…

  • Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

    DANVILLE, Pa., RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 25, 2017 /PRNewswire/ -- In an effort to improve health outcomes of people with type 2 diabetes, Geisinger and Boehringer Ingelheim, on behalf of its diabetes alliance with Eli Lilly and Company (NYSE: LLY), today announced a major collaboration to develop a risk-prediction model for three critical health outcomes commonly associated with t…

  • Lilly Takes Steps to Streamline Business, Invest in New Medicines and Drive Growth

    INDIANAPOLIS, Sept. 7, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced actions to streamline operations to more efficiently focus resources on developing new medicines and to improve its cost structure. Global workforce reductions, including those from a U.S. voluntary early retirement program, are expected to impact approximately 3,500 positions. With the streamlining…

  • Lilly to Participate in Morgan Stanley Global Healthcare Conference

    INDIANAPOLIS, Aug. 28, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2017. Derica Rice, Lilly's executive vice president for global services and chief financial officer, will participate in a fireside chat at 12:55 p.m., Eastern Time. A live audio webcast will be available on the "Webcasts & Present…

  • Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important role of cardiologists in reducing cardiovascular risk and cardiovascular death in people with type 2 diabetes

    RIDGEFIELD, Conn. and INDIANAPOLIS, July 31, 2017 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the companies will support an American College of Cardiology (ACC) program focused on driving quality improvement in cardiology and addressing the latest research advances in the reduction of cardiovascular risk and cardiovascular mortality in people wi…

  • Lilly Reports Second-Quarter Results

    INDIANAPOLIS, July 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2017. $ in millions, except per share data Second Quarter % 2017 2016 Change Revenue $ 5,824.3 $ 5,404.8 8% Net Income - Reported 1,008.0 747.7…

  • Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy

    INDIANAPOLIS and SAN FRANCISCO, July 24, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Nektar Therapeutics (NASDAQ: NKTR) have announced a strategic collaboration to co-develop NKTR-358, a novel immunological therapy discovered by Nektar. NKTR-358, which achieved first human dose in Phase 1 clinical development in March of 2017, has the potential to treat a number of autoimmune and o…

  • Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation

    INDIANAPOLIS, July 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has entered into a settlement agreement with generic companies to resolve pending patent litigation in the U.S. District Court for the Eastern District of Virginia regarding the Cialis® (tadalafil) unit dose patent. This patent was previously set to expire on April 26, 2020. As part of the agreement, Cialis exclusi…

  • Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk -- in honor of her mom

    RIDGEFIELD, Conn. and INDIANAPOLIS, May 16, 2017 /PRNewswire/ -- Award-winning actress Angela Bassett, along with 11 leading patient and professional organizations, is joining For Your SweetHeart™: Where diabetes and heart disease meet — a nationwide movement to raise awareness of the critical link between type 2 diabetes and heart disease, the number one killer of people with type 2…

  • Eli Lilly and Company Sponsors Arthritis Foundation 'Living Your Yes With RA,' an Initiative to Provide Resources for the Rheumatoid Arthritis Community

    INDIANAPOLIS, Oct. 12, 2016 /PRNewswire/ -- Supported by Eli Lilly and Company (NYSE: LLY), the Arthritis Foundation is launching 'Living Your Yes With RA,' a new initiative designed to empower people living with rheumatoid arthritis (RA) by giving them tools, education and resources, allowing them to expect more from their RA treatment - seeking remission or low disease activity as the only acce…

  • Lilly's First Volunteer Teams of 2016 Depart in May for Thailand and Ghana

    INDIANAPOLIS, May 19, 2016 /PRNewswire/ -- A team of Eli Lilly and Company (NYSE: LLY) volunteers from its operations worldwide is on the ground in Thailand, working with a local hospital and health volunteers as part of Lilly's Connecting Hearts Abroad global employee volunteer program. A second team of volunteers will depart next week to serve in Ghana. Nine more teams of Lilly volunteers will…

  • Lilly and United Way Celebrate Deepening Partnership, Community Impact

    INDIANAPOLIS, Nov. 5, 2015 /PRNewswire/ -- Representatives from Eli Lilly and Company (NYSE: LLY) and United Way and its partner agencies gathered today to celebrate the early success of a new partnership approach that includes pairing Lilly teams with United Way agencies and a record gift of $13 million. The results will be shared today from 4-6 p.m. at an Impact Celebration event hosted at the…

  • Diabetes Scholars Foundation Announces 2015 Scholarship Recipients

    ROLLING MEADOWS, Ill. and INDIANAPOLIS, June 25, 2015 /PRNewswire/ -- Attending college is a critical milestone in the lives of many young people. But balancing college life and a full course load while keeping a chronic disease such as diabetes in check can make an exciting time much more challenging. Today, the Diabetes Scholars Foundation (Foundation) announced its 2015 college scholarship rec…

  • Olympian Kris Freeman and NASCAR Driver Ryan Reed to Share Their Courageous Stories with Children Who Have Type 1 Diabetes

    INDIANAPOLIS, June 8, 2015 /PRNewswire/ -- Olympic cross-country skier Kris Freeman and NASCAR XFINITY Series driver Ryan Reed will travel across the U.S. this summer to share their stories of perseverance and triumph as part of the Lilly Camp Care Package (LCCP) program. Kris and Ryan will speak to children at select diabetes summer camps about how type 1 diabetes did not stop them from chasing…

  • Lilly commits 780,000 additional vials of insulin to Life for a Child

    INDIANAPOLIS, June 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) has committed another 780,000 vials of insulin to the International Diabetes Federation's Life for a Child program. Life for a Child provides free, life-saving medicine to children living in impoverished communities who otherwise would not have access to the insulin they need. The International Diabetes Federation (IDF) i…

  • Lilly Sends Employees to Serve in Vulnerable Communities around the World

    INDIANAPOLIS, May 27, 2015 /PRNewswire/ -- Marcio Donatelli, a senior marketing associate with the animal health division of Eli Lilly and Company (NYSE: LLY), believes his volunteer work in a healthcare setting in Bangkok, Thailand, will be among the most humbling experiences of his life. "Caring for people in need with respect and dignity is the guiding star for me and my fellow volunteers," sh…